Early study of KH617 for advanced brain and solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign informed consent
- Have advanced (not curable by surgery) solid cancer, or a recurrent/progressive adult diffuse glioma/GBM, with measurable targets on scan
- Have good enough blood counts and organ function on recent lab tests (for example: hemoglobin, platelets, liver and kidney tests)
- Have recovered from past cancer treatment side effects (no serious ongoing acute toxicity)
- Have an expected lifespan of at least 3 months
- For brain involvement: have at least one measurable/trackable brain lesion and be able to do daily activities (KPS 60 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This study tests a new experimental drug called KH815 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the drug is safe and how well it works against different types of cancer.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
This trial tests a new drug, Hemay181, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can shrink tumors and how safe it is.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.